Transplantationsmedizin – Quo vadis?

• Literatur

• 1 Weiner DE, Carpenter MA, Levey AS et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant 2012; 12: 2437-2445
• 2 Cibrik D, Silva HT Jr, Vathsala A et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013; 95: 933-942
• 3 Eisen HJ, Kobashigawa J, Starling RC et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013; 5: 1203-1216
• 4 Tedesco Silva S, Cibrik D, Johnston T et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 6: 1401-1413
• 5 De Simone P, Nevens F, De Carlis L et al.; H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 11: 3008-3020